TY - JOUR
T1 - The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma
AU - Rasche, Leo
AU - Angtuaco, Edgardo J.
AU - Alpe, Terri L.
AU - Gershner, Grant H.
AU - McDonald, James E.
AU - Samant, Rohan S.
AU - Kumar, Manoj
AU - Van Hemert, Rudy
AU - Epstein, Joshua
AU - Deshpande, Shayu
AU - Tytarenko, Ruslana
AU - Yaccoby, Shmuel
AU - Hillengass, Jens
AU - Thanendrarajan, Sharmilan
AU - Schinke, Carolina
AU - van Rhee, Frits
AU - Zangari, Maurizio
AU - Walker, Brian A.
AU - Barlogie, Bart
AU - Morgan, Gareth J.
AU - Davies, Faith E.
AU - Weinhold, Niels
N1 - Publisher Copyright:
© 2018 by The American Society of Hematology.
PY - 2018/7/5
Y1 - 2018/7/5
N2 - Spatial intratumor heterogeneity is frequently seen in multiple myeloma (MM) and poses a significant challenge for risk classifiers, which rely on tumor samples from the iliac crest. Because biopsy-based assessment of multiple skeletal sites is difficult, alternative strategies for risk stratification are required. Recently, the size of focal lesions (FLs) was shown to be a surrogate marker for spatial heterogeneity, suggesting that data from medical imaging could be used to improve risk stratification approaches. Here, we investigated the prognostic value of FL size in 404 transplant-eligible, newly diagnosed MM patients. Using diffusion-weighted magnetic resonance imaging with background suppression, we identified the presence of multiple large FLs as a strong prognostic factor. Patients with at least 3 large FLs with a product of the perpendicular diameters >5 cm2 were associated with poor progression-free survival (PFS) and overall survival (OS; median, 2.3 and 3.6 years, respectively). This pattern, seen in 13.8% of patients, was independent of the Revised International Staging System (RISS), gene expression profiling (GEP)–based risk score, gain(1q), or extramedullary disease (hazard ratio, 2.7 and 2.2 for PFS and OS in multivariate analysis, respectively). The number of FLs lost its negative impact on outcome after adjusting for FL size. In conclusion, the presence of at least 3 large FL is a feature of high risk, which can be used to refine the diagnosis of this type of disease behavior and as an entry criterion for risk-stratified trials.
AB - Spatial intratumor heterogeneity is frequently seen in multiple myeloma (MM) and poses a significant challenge for risk classifiers, which rely on tumor samples from the iliac crest. Because biopsy-based assessment of multiple skeletal sites is difficult, alternative strategies for risk stratification are required. Recently, the size of focal lesions (FLs) was shown to be a surrogate marker for spatial heterogeneity, suggesting that data from medical imaging could be used to improve risk stratification approaches. Here, we investigated the prognostic value of FL size in 404 transplant-eligible, newly diagnosed MM patients. Using diffusion-weighted magnetic resonance imaging with background suppression, we identified the presence of multiple large FLs as a strong prognostic factor. Patients with at least 3 large FLs with a product of the perpendicular diameters >5 cm2 were associated with poor progression-free survival (PFS) and overall survival (OS; median, 2.3 and 3.6 years, respectively). This pattern, seen in 13.8% of patients, was independent of the Revised International Staging System (RISS), gene expression profiling (GEP)–based risk score, gain(1q), or extramedullary disease (hazard ratio, 2.7 and 2.2 for PFS and OS in multivariate analysis, respectively). The number of FLs lost its negative impact on outcome after adjusting for FL size. In conclusion, the presence of at least 3 large FL is a feature of high risk, which can be used to refine the diagnosis of this type of disease behavior and as an entry criterion for risk-stratified trials.
UR - https://www.scopus.com/pages/publications/85049563332
UR - https://www.scopus.com/pages/publications/85049563332#tab=citedBy
U2 - 10.1182/blood-2018-04-842880
DO - 10.1182/blood-2018-04-842880
M3 - Article
C2 - 29784643
AN - SCOPUS:85049563332
SN - 0006-4971
VL - 132
SP - 59
EP - 66
JO - Blood
JF - Blood
IS - 1
ER -